Supported by an independent educational grant from Pfizer


No announcements have been made for this course


Skill level: All levels
Estimated time to complete activity: 30mins
Release date: January 10, 2023
Expiration date: October 31, 2024




Continuing Medical Education(CME), Continuing Nursing Education(CNE)


This session will be a practical basic science review on the immunology of AD and the role of the JAK/TEC pathway. 

Target Audience
This activity has been designed to meet the educational needs of clinicians and non-clinicians involved in the care of patients with atopic dermatitis.
Learning Objectives
After completing this activity, participants will be able to:
  1. Review the immune mechanisms involved in the pathogenesis of AD
  2. Describe emerging targets (such as JAK and TEC kinase related pathways) for AD and how their modulation affects inflammation
  3. Differentiate the immunological pathways of AD and the JAK/TEC inhibition pathways

Disclosure of Conflicts of Interest

Your CE Source ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, Your CE Source identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Your CE Source to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Your CE Source is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Faculty Reported Financial Relationship
James Song, MD

Speaker: AbbVie, Novartis, UCB, Eli Lily, Incyte, SUN, Amgen


Advisory Board: Janssen, Castle Bioscience, AbbVie, Novartis, UCB, Eli Lily, Acrutis, Incyte, SUN, Amgen


Research: SUN



Name of Editor/Scientific Reviewer Reported Financial Relationship
Peter Lio, MD


Speaker: Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, LEO, Galderma, Incyte, L'Oreal


Advisory Board: Almirall, ASLAN Pharmaceuticals, Dermavant, Regeneron/Sanofi, Genzyme, Pfizer, LEO Pharmaceuticals, AbbVie, Eli Lilly, Micreos, L'Oreal, Pierre-Fabre,  Johnson & Johnson, Level Ex, KPAway, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs, Galderma, Verrica, Arbonne, Amyris, Bodewell, YobeeCare, Burt's Bees, My-Or Diagnostics, Kimberly-Clark 


Research: AOBiome, Regeneron/Sanofi Genzyme, and AbbVie


Patent Holder: Theraplex AIM (Patent Pending)


Stockholder: Micreos, YobeeCare, and Altus Labs, KPAway, LearnSkin


The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Content Manager Reported Financial Relationship
Maria Mas, Planner No relationships with a commercial interest to disclose
Planners at Your CE Source No relationships with a commercial interest to disclose


All other faculty, planner and/or content managers have nothing to disclose nor do they have any vested interests or affiliations. All conflicts of interest have been resolved.

Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Your CE Source and LearnHealth. Your CE Source is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Your CE Source designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
This CE activity provides 1 contact hour of continuing nursing education. Your CE Source is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 16031.
Method of Participation
Participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the post test by recording the best answer to each quiz question, and 4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. Statements of credit will be available once the evaluation form is completed.
The content, views, and opinions presented in this educational activity are those of the faculty/authors and do not necessarily reflect those of Pfizer, Your CE Source, and/or LearnHealth. The faculty/authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Learners are required to adhere to the privacy and confidentiality policy as it relates to the CE activities provided on the Internet. Please see the policy at https://www.yourcesource.org


This activity is jointly provided by Your CE Source and LearnHealth.
Questions about CE accreditation or CE certificates related to this course, please contact us via email at adminsupport@yourcesource.org. For all other questions, please contact info@learnskin.com.